Kreon

Pancrelipase, the active ingredient in Kreon, is a pancreatic enzyme presented as a capsule for oral use. It treats exocrine pancreatic insufficiency in patients with cystic fibrosis, chronic pancreatitis, pancreatic cancer, or after pancreatectomy.

GNH USA supplies Kreon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kreon provides pancreatic enzyme replacement for conditions that impair endogenous enzyme production.

Exocrine pancreatic insufficiency due to cystic fibrosis: improves digestion and nutrient absorption. Chronic pancreatitis: supplies lipase, protease and amylase to aid digestion of fats, proteins and carbohydrates. Pancreatic cancer: supports digestive function when the tumor compromises pancreatic output. Post‑pancreatectomy: replaces missing pancreatic enzymes to maintain normal gastrointestinal nutrition.

Kreon may cause a range of gastrointestinal and systemic reactions.

Common Side Effects: - Abdominal discomfort or pain - Flatulence or bloating - Diarrhea or loose stools - Nausea or mild vomiting - Constipation - Indigestion or heartburn

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling) - Persistent abdominal pain or pancreatitis flare - Fecal incontinence - Significant weight loss despite therapy

Before prescribing Kreon, clinicians should consider several safety aspects.

Dose adjustment in renal or hepatic impairment: monitor for accumulation of enzyme fragments. Monitor for vitamin deficiencies: supplement fat‑soluble vitamins A, D, E, K as needed. Avoid in known hypersensitivity to porcine-derived products. Caution in patients with gastrointestinal obstruction or severe motility disorders. Consider acid‑suppressive therapy: proton pump inhibitors may reduce enzyme activity. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Kreon can interact with other medicines that alter gastric pH or affect fat absorption.

Major Interactions (Avoid): - Orlistat: may reduce absorption of fat‑soluble vitamins when used together. - High‑dose proton pump inhibitors: can markedly decrease enzyme activity, compromising efficacy.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium based): may modestly lower enzyme effectiveness. - Warfarin: monitor INR as changes in vitamin K absorption could affect anticoagulation. - Antibiotics that alter gut flora: may influence gastrointestinal tolerance.